 | • レポートコード：MRC2304J0211 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、244ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当市場調査レポートでは、世界のmRNA治療薬市場規模が、2021年219.8億ドルから2022年272.5億ドルへと成長し、更に年平均24.23％増大して2027年までに808.3億ドルに達すると予測しています。当書は、mRNA治療薬の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（予防ワクチン、治療薬、治療用ワクチン）分析、用途別（感染症、腫瘍、希少遺伝性疾患、呼吸器疾患）分析、最終用途別（病院＆クリニック、研究機関）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Abogen Biosciences、Alnylam Pharmaceuticals、Arcturus Therapeutics Holdings Inc.、Argos Therapeutics Inc.、AstraZeneca plc、BioNTech SE、CRISPR Therapeutics AG、CureVac N.V.、Deep Genomics、Eli Lilly and Company、GSK plc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のmRNA治療薬市場規模：種類別 - 予防ワクチンの市場規模 - 治療薬の市場規模 - 治療用ワクチンの市場規模 ・世界のmRNA治療薬市場規模：用途別 - 感染症における市場規模 - 腫瘍における市場規模 - 希少遺伝性疾患における市場規模 - 呼吸器疾患における市場規模 ・世界のmRNA治療薬市場規模：最終用途別 - 病院＆クリニックにおける市場規模 - 研究機関における市場規模 ・世界のmRNA治療薬市場規模：地域別 - 南北アメリカのmRNA治療薬市場規模 アメリカのmRNA治療薬市場規模 カナダのmRNA治療薬市場規模 ブラジルのmRNA治療薬市場規模 ... - アジア太平洋のmRNA治療薬市場規模 日本のmRNA治療薬市場規模 中国のmRNA治療薬市場規模 インドのmRNA治療薬市場規模 韓国のmRNA治療薬市場規模 台湾のmRNA治療薬市場規模 ... - ヨーロッパ/中東/アフリカのmRNA治療薬市場規模 イギリスのmRNA治療薬市場規模 ドイツのmRNA治療薬市場規模 フランスのmRNA治療薬市場規模 ロシアのmRNA治療薬市場規模 ... - その他地域のmRNA治療薬市場規模 ・競争状況 ・企業情報 |
The Global mRNA Therapeutics Market size was estimated at USD 21.98 billion in 2021 and expected to reach USD 27.25 billion in 2022, and is projected to grow at a CAGR 24.23% to reach USD 80.83 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the mRNA Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Prophylactic Vaccines, Therapeutic Drugs, and Therapeutic Vaccines.
Based on Application, the market was studied across Infectious Diseases, Oncology, Rare Genetic Diseases, and Respiratory Diseases.
Based on End Use, the market was studied across Hospitals & Clinics and Research Organizations.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for mRNA Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the mRNA Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global mRNA Therapeutics Market, including Abogen Biosciences, Alnylam Pharmaceuticals, Arcturus Therapeutics Holdings Inc., Argos Therapeutics Inc., AstraZeneca plc, BioNTech SE, CRISPR Therapeutics AG, CureVac N.V., Deep Genomics, Eli Lilly and Company, GSK plc., Ionis Pharmaceuticals, Laronde Inc., Moderna, Inc., Nutcracker Therapeutics Inc., Pfizer Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Sirnaomics Inc., and Translate Bio, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global mRNA Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global mRNA Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global mRNA Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global mRNA Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global mRNA Therapeutics Market?
6. What is the market share of the leading vendors in the Global mRNA Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global mRNA Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chronic and infectious diseases
5.1.1.2. Growing demand for cancer vaccines and treatments
5.1.1.3. Upsurge demand for mRNA therapeutics and proliferation of government initiatives for large scale sequencing projects
5.1.2. Restraints
5.1.2.1. High cost of research and threat of failure in quantification of mRNA
5.1.3. Opportunities
5.1.3.1. Significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology
5.1.3.2. Development of personalized therapeutics for cancer with strong pipeline of new products
5.1.4. Challenges
5.1.4.1. Regulatory concerns and strategies for mRNA therapeutics
5.2. Cumulative Impact of COVID-19
6. mRNA Therapeutics Market, by Type
6.1. Introduction
6.2. Prophylactic Vaccines
6.3. Therapeutic Drugs
6.4. Therapeutic Vaccines
7. mRNA Therapeutics Market, by Application
7.1. Introduction
7.2. Infectious Diseases
7.3. Oncology
7.4. Rare Genetic Diseases
7.5. Respiratory Diseases
8. mRNA Therapeutics Market, by End Use
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Research Organizations
9. Americas mRNA Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific mRNA Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa mRNA Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abogen Biosciences
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Alnylam Pharmaceuticals
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Arcturus Therapeutics Holdings Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Argos Therapeutics Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. AstraZeneca plc
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. BioNTech SE
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. CRISPR Therapeutics AG
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. CureVac N.V.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Deep Genomics
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Eli Lilly and Company
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. GSK plc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Ionis Pharmaceuticals
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Laronde Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Moderna, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Nutcracker Therapeutics Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Pfizer Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sangamo Therapeutics, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sarepta Therapeutics
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sirnaomics Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Translate Bio, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing